

Review Article

Therapeutic Applications of Nanozymes in Chronic Inflammatory Diseases

Haojue Wang,¹ Zichen Cui,^{2,3} Xuan Wang,^{4,5,6} Shui Sun,^{2,3} Dongsheng Zhang,^{4,5,6} and Chuanyun Fu D^{4,5,6}

¹School of Queen Mary, Nanchang University, Xuefu Avenue, Nanchang, Jiangxi 330031, China

²Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China

³Orthopaedic Research Laboratory, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China

⁴Department of Stomatology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, China

⁵Department of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China

⁶School of Stomatology, Shandong First Medical University, Jinan, Shandong 250021, China

Correspondence should be addressed to Chuanyun Fu; fuchuanyun@sdfmu.edu.cn

Received 1 April 2021; Revised 12 June 2021; Accepted 31 July 2021; Published 11 August 2021

Academic Editor: Dongliang Xu

Copyright © 2021 Haojue Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Since the discovery of horseradish peroxidase-like activity of magnetite nanoparticles in 2007, many researchers have investigated different types of nanoparticles that show enzyme-like activities, namely, nanozymes. Nanozymes possess high efficiency, stability, and low production costs compared to natural enzymes. Thus, nanozymes have already been widely studied in various domains including medical science, food industry, chemical engineering, and agriculture. This review presents the utilization of nanozymes in medicine and focuses particularly on their therapeutic applications in chronic inflammatory diseases because of their antioxidant-like activity. Furthermore, the treatment of chronic inflammatory diseases with nanozymes of different materials was introduced emphatically.

1. Introduction

Enzymes are biocatalysts with high efficiency that are highly selective to their specific substrates, but they also have some inherent defects such as low stability and high production cost, which limit their application [1]. Therefore, identifying enzyme mimics is an important study.

In 2007, it was discovered that magnetite nanoparticles possessed an activity similar to the enzyme-like property of horseradish peroxidases [2]. Further studies showed that these metallic nanoparticles exhibited an enzyme-like activity and were defined as nanozymes. These include nanoparticles that exhibit enzyme-like activities of peroxidase [3], catalase (CAT) [4], superoxide dismutase (SOD) [5], and hydrolase [6]. The most prominent characteristic of nanozymes is that the size of the nanoparticles is less than 100 nm in at least one dimension, which means they can be regarded as two-dimensional sheets with a high specific surface area and thus have excellent catalytic activities [7]. Moreover, the metallic nature of the nanozymes helps them in sustaining in hostile environments, such as high temperature, acidic environment, or alkaline environment; thus, nanozymes are more stable than natural enzymes [8]. Moreover, some nanozymes show unique characteristics and have low production costs compared to natural enzymes [9].



FIGURE 1: Brief diagram of the nanozyme-based H_2O_2 sensor and its application in the detection of cholesterol, glucose, and galactose.

2. Application of Nanozyme in Medicine

2.1. Nanozyme-Based Sensors

2.1.1. H_2O_2 Sensors. Hydrogen peroxide is the most popular and detectable reactive oxygen species (ROS), which is formed by the reduction of oxygen. When the formation of ROS abnormally increases, H₂O₂ causes oxidative damage in vivo by targeting the DNA, proteins, and biofilms [10]. The sensing of H₂O₂ utilizes the nanozyme with peroxidaselike activity, such as iron-based nanoparticles (NPs) (with the detection limit of $50 \,\mu\text{M}$) [11], vanadium-based NPs (with the detection limit of $0.5 \,\mu\text{M}$ [12], and metal-organic framework-based nanocomposites (NCs) (with the detection limit of $0.24 \,\mu\text{M}$ [13] to catalyze the oxidation of 3.3', 5.5'tetramethylbenzidine (TMB) by H₂O₂ to generate a bluecolored product, 3,3',5,5'-tetramethylbenzidine (oxTMB) (Figure 1). Apart from this colorimetric reaction, scientists have also developed other methods for sensing H₂O₂ using an electrochemical process [14], fluorometric sensor [15], and Raman scattering sensor [16].

The sensing of H_2O_2 is quite important in the research of nanozyme, not only for the physiological effects of H_2O_2 but also due to the fact that detection of H_2O_2 is usually coupled with the sensing of other biomolecules or chemical particles such as biothiols [17], dopamine [18], metal ions [19–21], histidine, and Cu²⁺ [22], which can inhibit or stabilize the peroxidase-like activity of nanozymes and indirectly mediate the oxidative generation of TMB (Figure 1). Furthermore, some biomolecules like cholesterol [23], glucose [24], and galactose [25] can be oxidized by their oxidases to generate H_2O_2 ; so, combining these two reactions can help quantify the molecules easily (Figure 1). Due to the sensitivity of nanozymes to detect H_2O_2 , it can also sense these molecules.

2.1.2. Nanozyme-Based Enzyme-Linked Immunosorbent Assay (ELISA). ELISA is a labelled immunoassay which is widely used in clinical laboratory to quantificationally detect antigens like cancer markers, proteins, viruses, and hormones.

Traditional ELISA is based on the activity of natural enzymes and the unique interaction between the antigen and the antibody [26], but preparation and purification, as well as preservation of these enzymes, are expensive and laborious [27]. The development of nanozyme offers an alternative solution.

Oh et al. developed an ultrasensitive ELISA to detect the influenza A virus [28]. This method utilizes magnetic nanobead capture probes and Au nanozyme probes to detect the influenza A virus. The Au nanozyme probes were made of Au NPs, which have higher stability and activity than traditional horseradish peroxidase, and antiinfluenza virus antibodies (Ab2 or Ab3). The magnetic nanobead capture probes were made of magnetic nanobeads and anti-influenza virus antibodies (Ab1 or Ab3) (Figure 2(a)). Then, both of these were mixed, and they formed a sandwich structure with the influenza A virus; this structure was selected by a magnet. Then, the Au nanozyme probe with peroxidase-like activity catalyzed H_2O_2 to oxidize TMB into oxTMB (Figure 2(b)) [28].

Similar methods that use nanozymes with peroxidaselike activity (usually Au or Au alloy NPs) as the enzyme complex and TMB as the chromogenic substance are very useful for detecting different antigens. It has been employed for the detection of *Escherichia coli* [29], coronavirus [30], norovirus [31], and measles virus [32].

2.2. Nanozyme-Based Therapy

2.2.1. Cancer Therapy. The application of nanozyme in cancer therapy can be classified into two categories. The first is a direct method, the basic principle of which is to generate ROS in tumor tissues utilizing the peroxidase-like activity and oxidase-like activity of nanozymes. Gao et al. designed a nanoplatform by integrating Au NPs and iron oxide NPs into dendritic mesoporous silica nanoparticles which served as the glucose oxidase to catalyze the oxidation of glucose to generate H_2O_2 . Then, iron oxide converts H_2O_2 into high cytotoxic hydroxyl radicals by means of a Fenton-like



FIGURE 2: The preparation of the Au nanozyme probes and the magnetic capture nanobead probes and the procedure of this ELISA (cited from Scheme 1 of Oh et al. [28]).

reaction, which finally leads to the apoptosis of the cancer cells [33].

Radiotherapy and photodynamic therapy (PDT) are common therapeutics for cancer which are facilitated by the production of ROS [34]. But the generation of ROS needs oxygen, which is always deficient in cancer tissues [34]. So, the other method is to use catalase-mimic nanozymes to increase local oxygen concentration and indirectly improve the efficiency of radiotherapy and PDT to cancer tissues. Li et al. successfully synthesized porous platinum NPs which are catalase-mimic nanozymes that react with H_2O_2 and produce oxygen, which then effectively enhance the radiation dose in the targeted tumor tissues [35]. Similar effects were also reported by Hao et al. in PDT [36].

2.2.2. Neuroprotection. Generation of ROS can be used in cancer therapy, but the overproduction of ROS is the pathological marker of many diseases, especially those that affect the neuro system. Prussian blue (PB) can effectively remove ROS due to its catalase-, superoxide dismutase-,

and peroxidase-mimic activities. Based on these characteristics, Zhang et al. developed a hollow PB nanozyme which protects the neuro system against ischemic shock by scavenging ROS, relieving inflammation, and controlling cellular apoptosis [37].

2.2.3. Anti-Inflammation. Because of the multienzymemimic activities, nanozymes display excellent ability in regulating oxidation-regulation reaction [37]. Inflammation is a pathological response that is intended to eliminate inflammatory stimuli and initiate tissue repair. Overproduction of ROS is an important characteristic of chronic inflammation, which leads to redox imbalance. Thus, restoring redox homeostasis is an important method to relieve inflammation reaction. Besides Alzheimer's disease and ischemic shock, nanozymes can also reduce the ROS level and resist inflammation in chronic inflammatory diseases.

Thus, we can summarize that nanozymes have been extensively studied in biomedical domains because of their unique characteristics. Herein, we will categorize nanozymes systematically and introduce their therapeutic applications in chronic inflammatory diseases.

3. Chronic Inflammatory Diseases

Chronic inflammation is a response to long-term inflammation, tissue injury, and attempted repair, which are usually caused by persisting infections, hypersensitivity diseases, and prolonged exposure to potentially toxic agents [38]. Typical chronic inflammatory diseases include Alzheimer's disease, Crohn's diseases, ulcerative colitis, rheumatoid arthritis, and periodontitis [39]. Inflammatory reaction is the collective characteristic of these diseases which includes vasodilation, increased vascular permeability, and leukocyte infiltration and activation [38]. The main method by which activated leukocytes recognize and eliminate the microbes or necrotic tissues is through phagocytosis, which mainly relies on ROS. H_2O_2 , an ROS, then forms the H_2O_2 -MPO-halide system, which is the most efficient sterilization system [38].

Although ROS as a physiological substance helps maintain hemostasis in normal condition, but the overproduction of ROS in chronic inflammatory reaction is highly toxic to normal tissue, its activity must be controlled *in vivo* by antioxidant mechanisms which involves enzymes like catalase, superoxide dismutase, and glutathione peroxidase [38]. The cause of most of the chronic inflammatory diseases is unclear, and so, the therapy for these diseases usually targets its inflammatory reaction [40]. Thus, the mimics of these enzymes may be potential drugs to relieve the inflammatory reaction and treat chronic inflammatory diseases.

An increasing number of researches have been performed toward the treatment of chronic inflammatory diseases. Using glucocorticoids to inhibit immune reaction and using nonsteroidal anti-inflammatory drugs (NSAID) to inhibit the biosynthesis of cyclooxygenase are the two major means used in clinical application to attenuate inflammation, which have extensive side effects of gastrointestinal complications, cardiovascular complications, and inducing or aggravating infection, among others [41-45]. Hence, identifying other anti-inflammatory agents is of utmost importance. Among these, antioxidants are widely sought after, and quite a few of antioxidants such as curcumin [46], polyphenol [47], chlorogenic acid [48], and ascorbic acid [49] have been reported for their anti-inflammatory potential. Some of these have already been used in clinical therapy. Thus, nanozyme, as the high-efficiency mimic of antioxidant enzyme, is no doubt a considerable option for chronic inflammatory disease therapy.

4. Therapeutic Applications of Nanozymes in Chronic Inflammatory Diseases

4.1. Cerium Oxide-Based Nanomaterial. Cerium oxide-based nanozymes are widely used in many fields, such as medicine, because of their unique characteristics. Cerium oxide NPs have superoxide dismutase-, catalase-, and oxidase-like activities [50, 51]. Furthermore, cerium oxide-based nanozymes are stable in both acidic and basic conditions. At physiologi-

cal pH values (pH7.4), cerium oxide-based nanozymes perform great SOD- and CAT-like activities; thus, the nanozymes can protect cells from oxidants, but under acidic conditions (pH 4.5), the oxidase-like activity of cerium oxide-based nanozymes can effectively kill cancer cells by producing ROS [52].

Some studies showed that the Ce^{3+}/Ce^{4+} ratio depends on the CAT- and SOD-like activities, and cerium oxide nanoparticles can simulate the chemical reaction and antioxidant activity of CAT and SOD [53]; thus, it can protect cells by regulating the level of ROS in cells.

One of the important functions of cerium oxide nanoparticles is inhibiting inflammatory mediators and protecting the cell structure from inflammatory diseases. Inflammation *in vivo* and *in vitro* can be effectively treated by scavenging free radicals or ROS [54]. Arya et al. [55] synthesized spherical cerium oxide nanozymes as an anti-inflammatory drug to evaluate the protective effect of hypoxia on the lung. After repeated intraperitoneal injection, CeO₂ was deposited in the lung, which reduced the oxidation of active oxygen and lipid, thus protecting the lung from oxidative stress and tissue damage caused by the endotoxin.

Studies have shown that the ceria nanozyme is very effective in neuroprotection. Alzheimer's disease is an insidious disease characterized by progressive neurodegenerative changes including amyloid-beta peptide aggregates, overproduction of ROS, and inflammatory reactions. Based on these pathological markers, Guan et al. [56] designed a ceria/ polyoxometalate hybrid with SOD and proteolytic activities (Figure 3). This nanozyme could cross the blood-brain barrier, degrade amyloid-beta peptide aggregates, reduce the ROS levels, boost the proliferation of PC12 cells, and inhibit the activation of BV2 microglia cells induced by the amyloidbeta peptides. Thus, it provides an evidence for the therapeutic application of nanozymes in Alzheimer's disease.

Scientists have also developed an effective anti-ischemic treatment agent based on monodispersed ceria nanoparticles, which are loaded with edaravone and modified with angiopep-2 and poly (ethylene glycol) on their exterior [57]. This material can effectively treat stroke by eliminating ROS, as it can greatly enhance the brain uptake; simultaneously, it can effectively protect the blood-brain barrier and thus has great potential in stroke treatment.

Parkinson's disease is a hypokinetic disorder disease, which is characterized by the failure of the disinhibition that is normally mediated by the basal ganglia. The direct cause of Parkinson's disease is the loss of the substantia nigra pars compacta due to cell death. Kwon et al. [58] used CeO₂ to enhance the activities of SOD and CAT enzymes and remove ROS inside and outside the cells to prevent the initiation of microglia and peroxidation of lipid and to protect tyrosine hydroxylase to treat Parkinson's disease.

As mentioned above, these experiments present the excellent ROS-reducing ability of ceria NPs inside and outside the cells, which greatly alleviates the oxidative stress in the brain and lung [55–58]. Curative effects of ceria NPs are shown in animal models with Parkinson's, stroke, and lung inflammation. Thus, the broad potentials of ceria NPs are shown in anti-inflammation therapy. But what needs



FIGURE 3: (a) Schematic structure of ceria/polyoxometalate hybrid molecule. (b) Electron microscope image of ceria/polyoxometalate hybrid molecule (cited from Figure 1 of Guan et al. [56]).

consideration is how the ceria NPs are eliminated from the body, if the ceria NPs possessed biological toxicity, and also the stability and activity of this nanozyme. Hence, deeper research on ceria NPs is still needed.

4.2. Iron Oxide-Based Nanomaterial. Iron oxide-based nanozymes are great peroxidase mimics with excellent stability. Even when placed in high temperatures of 90°C and pH value from 1.5 to 12.0 for 2 hours, iron oxide-based nanozymes can still retain its catalytical activity, which is much better than the natural enzyme, which rapidly loses its activity at 40°C and pH value of 5.0 [59].

At present, iron oxide-based nanozymes have certain value in the treatment of chronic inflammatory diseases, but their usage as antioxidants has therapeutic effects in nervous system diseases [60]. *In vivo*, researchers demonstrated that iron oxide NPs protect cells from oxidative stress and apoptosis induced by H_2O_2 . Also, iron oxide NPs can relieve intracellular oxidative stress, postpone animal aging, and prevent neurodegeneration because of their catalase-like activity. *In vitro*, the level of ROS of PC12 cells, which were exposed to MPP+, declined greatly due to the treatment of iron oxide NPs, and the death of the PC12 cells was alleviated. Therefore, the function of iron oxide NPs in the therapy of Parkinson's disease has been evaluated [60].

In addition, researchers used the Drosophila Alzheimer's disease model to examine the effects of iron oxide NPs on neuronal dysfunction. They found that dietary iron oxide NPs can improve neurodegeneration, due to the decomposition of ROS by iron oxide NPs. Another study developed a ferritin nanozyme (Fenozyme) formed by recombinant human ferritin (HFn) protein shells [61]. This nanozyme can not only specifically target blood-brain barrier endothelial cells (the effect of HFn) but also exhibits catalase-like activity to scavenge ROS. An *in vivo* experiment showed that

Fenozyme significantly improved the destruction of the blood-brain barrier caused by parasites and significantly promoted the survival of infected mice.

In addition, it has been verified that iron oxide NPs have a protective effect on cardiomyocytes, because they have catalase- and peroxidase-like activities and are used in antioxidant therapy. Xiong et al. [62] reported that Fe_2O_3 -DMSA NPs can preserve the heart from ischemic injury by inhibiting intracellular ROS in several ways and relieve the peroxidation injury of the membrane lipid.

The above experiments preliminarily demonstrate the peroxidase- and catalase-like activities of iron oxide NPs, which can effectively eliminate superfluous H_2O_2 generated under oxidative stress or produced through SOD and also successfully protect myocardial and neural cells [60–62]. An even better curative effect was observed in mice with myocardial ischemia and reperfusion, which were treated with iron oxide NPs compared to when the same model was treated with verapamil. No apparent cytotoxicity was observed in iron oxide NPs with the dosage between 0.01 and 0.5 mg ml⁻¹.

4.3. Manganese-Based Nanomaterial. MnO_2 NPs have been proven to have a variety of enzyme-like activities such as peroxidase-, oxidase-, catalase-, SOD-, and glutathione peroxidase-like activities, and they are more stable than natural enzymes. Therefore, MnO_2 NPs have broad applications in different aspects, such as biotechnology, bioassays, and biomedicine [63]. Due to the abnormal increase in ROS level, the balance of redox *in vivo* will be destroyed, which will cause oxidative stress, and ultimately leads to the destruction of the structure and function of cellular macromolecules. The peroxidase- and SOD-like activities of nanozymes are generally utilized to control the level of ROS in cells, and this function plays an important role in protecting the cells.



FIGURE 4: The basic mechanisms of the working of SOD-, CAT-, and GPx-mimic nanozymes in ROS-imbalanced cells (cited from the graphical abstract of Singh et al. [65]).

Singh et al. [64] found that Mn_3O_4 NPs with flower-like morphology performed the activities of several antioxidant enzymes such as SOD, CAT, and glutathione peroxidase. These activities are related to the mixed oxidation states of manganese, unusually large-sized pore, high stability against irreversible oxidation, and large surface area. They have proven that the multienzyme mimic, Mn₃O₄ nanoflowers, could modulate the redox status of the cells caused by oxidative stress by protecting biomolecules from protein oxidation, lipid peroxidation, and DNA damage mediated by ROS (Figure 4). Furthermore, these nanozymes, with the ability to mimic the cellular antioxidant enzymes to protect cell from oxidative damage, will not alter the response of Nrf2 protein under oxidative stress, so the nanozymes can regulate the redox homeostasis of cells without interfering with the antioxidant proteins/enzymes in the cells [65]. Also, the Mn₃O₄ nanoflowers showed great ability to save the cells from ROS-mediated inflammatory injury and prevent neurological diseases, such as Parkinson's, caused by the imbalance of ROS.

Besides the multienzyme-mimic activity, the high catalytic capacity of Mn_3O_4 NPs, compared to not only the natural enzyme but also other NPs, is an amazing finding. Mn_3O_4 NPs showed better ability in the scavenging of oxygen radical and hydroxyl radical when compared to Fe²⁺ and CeO₂ NPs; thus, Mn_3O_4 NPs exhibited greater anti-inflammatory ability. Based on this, Yao et al. designed a strategy to cure ear inflammation in mice [66].

The multiple enzyme-mimic activities and the comparative high catalytic activities are the major characteristics of manganese-based nanomaterial, which are rarely found in other nanozymes [63]. This implies that manganese-based nanomaterials can protect cells from ROS-induced cell injury and inflammatory reaction without disturbing the inherent antioxidation system of the cells. Thus, manganese-based nanozymes can be a good choice for the treatment of chronic inflammation with broad prospect.

4.4. Gold- and Platinum-Based Nanomaterials. Gold nanomaterials have entered public sight as a nanozyme material because of the function of mimicking oxidase. In order to play a better role in simulating enzyme activity, some studies have used gold nanoparticles along with other materials to synthesize nanostructures, such as Au-Pt.

In the field of cell protection, gold nanozyme showed great antioxidant properties and highly catalytic activity. Keratinocytes are most affected by ultraviolet (UV) light irradiation, because these cells are located in the outermost layer of skin. UV-induced cell damage is caused by superfluous ROS. Xiong et al. [67] prepared enzyme-mimic Au-Pt NCs to catalyze the clearance of ROS. They have demonstrated that the active and biocompatible Au-Pt NCs can eliminate ROS induced by UV rays and prevent subsequent oxidative damage to cells *in vivo*.

4.5. Platinum-Based Nanomaterial. The major utilization of platinum in medicine is in anticancer therapy such as cisplatin, carboplatin, and oxaliplatin. With increased research in metal NPs, researchers have identified its excellent ability in anti-inflammation. Similar to other nanozymes, platinum NPs (PtNPs) performing as SOD and CAT mimics can eliminate ROS and reduce oxidative stress. Furthermore, PtNPs are different from other enzymes as they can directly inhibit the overproduction of nitric oxide, tumor necrosis factor- α , interleukin-6, and other inflammatory mediators; they can also inhibit the activity of macrophages through inhibition of the NF- κ B signaling pathway. Based on this comprehensive anti-inflammation ability, oral PtNPs produced a marked effect in mouse colitis which greatly alleviated local and systemic inflammatory reaction [68]. Similar effects were

also observed in the prevention of pneumonia in mice exposed to smoke [69].

Although PtNPs are great antioxidants, they can be easily oxidized in air, but combining them with PdNPs can solve this problem and broaden the application of PtNPs. Shibuya et al. [70] used a mixture of PdNPs and PtNPs, namely, PAPLAL, to treat chronic diseases. Besides, due to the SOD- and catalase-like activities of PAPLAL, it can inhibit the intrinsic superoxide *in vivo* and treat aging-related skin diseases caused by oxidative stress.

4.6. Carbon-Based Nanomaterial. Carbon-based nanomaterials have been widely used in biomedicine. Compared to natural enzymes, carbon nanomaterials have higher stability and lower cost.

Fullerene is the first carbon-based nanozyme that has been found to possess SOD-like activity. C3 is a first-inclass functionalized water-soluble fullerene, and it has been confirmed that C3 can reduce ROS, which has been shown to be related to neurodegenerative diseases *in vitro*. Dugan et al. [71] found that after the treatment of the potent antioxidant C3, Parkinsonian motor ratings significantly improved in monkeys and the striatal dopamine levels increased. Even though the damage process had begun, C3 could reduce striatal injury. Furthermore, C3 has anti-inflammatory properties which can reduce MPTP- and 6-hydroxydopamine-induced neuronal cell death by reducing oxidative damage. These studies found little evidence of toxicity for C3.

4.7. Summary. Natural enzymes require strict physiological conditions for performing catalytic functions. Their limited stability in harsh environmental conditions and other significant drawbacks such as the high cost of synthesis, isolation, and purification greatly limit their practical applications [72]. Therefore, to address the limitations of natural enzymes, nanozymes have attracted considerable interest over the past decade owing to their obvious advantages. Nanozymes are nanomaterials with intrinsic enzyme-like characteristics which can offer unflinching biocatalytic activity even in the extreme conditions of pH, temperatures, and resistance to the digestion from proteases. Their advantages also include low cost, easy large-scale production, high stability, and smooth surface modification of nanomaterials [2, 72]. Moreover, the unique physicochemical properties of nanomaterials not only endow nanozymes with multiple functionalities but also provide more possibilities for rational design and future applications. As an alternative to natural enzymes, the antioxidant effects of nanozymes have been extensively explored for antiaging, anti-inflammatory, antioxidative, and neuroprotective functions and in the treatment of Alzheimer's and Parkinson's disease [73].

Although it is well established that nanozymes possess several distinct advantages over natural enzymes, they still face several limitations. Biological enzymes are highly selective to their targets; however, nanozymes show limited selectivity toward their substrates. So far, most studies focused on the activity regulation and only a few on their selectivity [74].

7

Conflicts of Interest

All authors declare there is no conflict of interest.

Authors' Contributions

Haojue Wang and Zichen Cui contributed equally to this work.

Acknowledgments

Research reported in this publication was supported by the Natural Science Foundation of Shandong Province, China (Grant No. ZR2020QH157).

References

- A. Sun, L. Mu, and X. Hu, "Graphene oxide quantum dots as novel nanozymes for alcohol intoxication," ACS Applied Materials & Interfaces, vol. 9, no. 14, pp. 12241–12252, 2017.
- [2] L. Gao, J. Zhuang, L. Nie et al., "Intrinsic peroxidase-like activity of ferromagnetic nanoparticles," *Nature Nanotechnology*, vol. 2, no. 9, pp. 577–583, 2007.
- [3] Z. Zhang, Y. Tian, P. Huang, and F. Y. Wu, "Using targetspecific aptamers to enhance the peroxidase-like activity of gold nanoclusters for colorimetric detection of tetracycline antibiotics," *Talanta*, vol. 208, p. 120342, 2020.
- [4] X. E. Zhao, Y. N. Zuo, X. Qu, J. Sun, L. Liu, and S. Zhu, "Colorimetric determination of the activities of tyrosinase and catalase via substrate-triggered decomposition of MnO₂ nanosheets," *Mikrochimica Acta*, vol. 186, no. 12, p. 848, 2019.
- [5] J. Xi, G. Wei, L. An et al., "Copper/carbon hybrid nanozyme: tuning catalytic activity by the copper state for antibacterial therapy," *Nano Letters*, vol. 19, no. 11, pp. 7645–7654, 2019.
- [6] L. Uribe, G. Diezemann, J. Gauss, J. P. Morth, and M. Cascella, "Structural origin of metal specificity in isatin hydrolase from-Labrenzia aggregataInvestigated by computer simulations," *Chemistry*, vol. 24, no. 20, pp. 5074–5077, 2018.
- [7] E. A. Bleeker, W. H. de Jong, R. E. Geertsma et al., "Considerations on the EU definition of a nanomaterial: science to support policy making," *Regulatory Toxicology and Pharmacology*, vol. 65, no. 1, pp. 119–125, 2013.
- [8] S. Sabale, P. Kandesar, V. Jadhav, R. Komorek, R. K. Motkuri, and X. Y. Yu, "Recent developments in the synthesis, properties, and biomedical applications of core/shell superparamagnetic iron oxide nanoparticles with gold," *Biomaterials Science*, vol. 5, no. 11, pp. 2212–2225, 2017.
- [9] S. Maddela, A. Makula, and N. Jayarambabu, "Fe₃O₄ nanoparticles mediated synthesis of novel isatin-dihydropyrimidinone hybrid molecules as antioxidant and cytotoxic agents," *Anti-Cancer Agents in Medicinal Chemistry*, vol. 17, no. 3, pp. 456–463, 2017.
- [10] V. Cecarini, J. Gee, E. Fioretti et al., "Protein oxidation and cellular homeostasis: emphasis on metabolism," *Biochimica et Biophysica Acta*, vol. 1773, no. 2, pp. 93–104, 2007.
- [11] N. V. S. Vallabani, A. S. Karakoti, and S. Singh, "ATPmediated intrinsic peroxidase-like activity of Fe₃O₄-based nanozyme: one step detection of blood glucose at physiological pH," *Colloids and Surfaces. B, Biointerfaces*, vol. 153, pp. 52–60, 2017.

- [13] Y. Zhang, J. Song, Q. Pan et al., "An Au@NH2-MIL-125(Ti)based multifunctional platform for colorimetric detections of biomolecules and Hg²⁺," *Journal of Materials Chemistry B*, vol. 8, no. 1, pp. 114–124, 2020.
- [14] Y. Xie, M. Xu, L. Wang, H. Liang, L. Wang, and Y. Song, "Ironporphyrin-based covalent-organic frameworks for electrochemical sensing H₂O₂ and pH," *Materials Science & Engineering. C, Materials for Biological Applications*, vol. 112, p. 110864, 2020.
- [15] X. Huang, H. Zhou, Y. Huang et al., "Silver nanoparticles decorated and tetraphenylethene probe doped silica nanoparticles: a colorimetric and fluorometric sensor for sensitive and selective detection and intracellular imaging of hydrogen peroxide," *Biosensors & Bioelectronics*, vol. 121, pp. 236–242, 2018.
- [16] Y. Li, Y. Wang, C. Fu et al., "A simple enzyme-free SERS sensor for the rapid and sensitive detection of hydrogen peroxide in food," *Analyst*, vol. 145, no. 2, pp. 607–612, 2020.
- [17] Y. Sun, J. Wang, W. Li, J. Zhang, Y. Zhang, and Y. Fu, "DNAstabilized bimetallic nanozyme and its application on colorimetric assay of biothiols," *Biosensors & Bioelectronics*, vol. 74, pp. 1038–1046, 2015.
- [18] M. X. Guo and Y. F. Li, "Cu (II)-based metal-organic xerogels as a novel nanozyme for colorimetric detection of dopamine," *Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy*, vol. 207, pp. 236–241, 2019.
- [19] Y. Tang, Y. Hu, Y. Yang, B. Liu, and Y. Wu, "A facile colorimetric sensor for ultrasensitive and selective detection of lead(II) in environmental and biological samples based on intrinsic peroxidase-mimic activity of WS₂ nanosheets," *Analytica Chimica Acta*, vol. 1106, pp. 115–125, 2020.
- [20] Y. Wang, J. Hu, Q. Zhuang, and Y. Ni, "Enhancing sensitivity and selectivity in a label-free colorimetric sensor for detection of iron(II) ions with luminescent molybdenum disulfide nanosheet- based peroxidase mimetics," *Biosensors & Bioelectronics*, vol. 80, pp. 111–117, 2016.
- [21] C. Ma, Y. Ma, Y. Sun et al., "Colorimetric determination of Hg²⁺ in environmental water based on the Hg²⁺-stimulated peroxidase mimetic activity of MoS₂-Au composites," *Journal* of Colloid and Interface Science, vol. 537, pp. 554–561, 2019.
- [22] Y. Liu, D. Ding, Y. Zhen, and R. Guo, "Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine," *Biosensors & Bioelectronics*, vol. 92, pp. 140–146, 2017.
- [23] C. Hong, X. Zhang, C. Wu et al., "On-site colorimetric detection of cholesterol based on polypyrrole nanoparticles," ACS Applied Materials & Interfaces, vol. 12, no. 49, pp. 54426– 54432, 2020.
- [24] Y. M. Wang, J. W. Liu, J. H. Jiang, and W. Zhong, "Cobalt oxyhydroxide nanoflakes with intrinsic peroxidase catalytic activity and their application to serum glucose detection," *Analytical and Bioanalytical Chemistry*, vol. 409, no. 17, pp. 4225–4232, 2017.
- [25] X. Zhou, M. Wang, J. Chen, X. Xie, and X. Su, "Peroxidase-like activity of Fe-N-C single-atom nanozyme based colorimetric detection of galactose," *Analytica Chimica Acta*, vol. 1128, pp. 72–79, 2020.

- [26] M. Alhajj and A. Farhana, Enzyme linked immunosorbent assay, StatPearls, Treasure Island, FL, USA, 2020.
- [27] Y. Ju and J. Kim, "Dendrimer-encapsulated Pt nanoparticles with peroxidase-mimetic activity as biocatalytic labels for sensitive colorimetric analyses," *Chemical Communications*, vol. 51, no. 72, pp. 13752–13755, 2015.
- [28] S. Oh, J. Kim, V. T. Tran et al., "Magnetic nanozyme-linked immunosorbent assay for ultrasensitive influenza A virus detection," ACS Applied Materials & Interfaces, vol. 10, no. 15, pp. 12534–12543, 2018.
- [29] J. Han, L. Zhang, L. Hu et al., "Nanozyme-based lateral flow assay for the sensitive detection of _Escherichia coli_ O157:H7 in milk," *Journal of Dairy Science*, vol. 101, no. 7, pp. 5770–5779, 2018.
- [30] G. Nikaeen, S. Abbaszadeh, and S. Yousefinejad, "Application of nanomaterials in treatment, anti-infection and detection of coronaviruses," *Nanomedicine*, vol. 15, no. 15, pp. 1501–1512, 2020.
- [31] I. M. Khoris, K. Takemura, J. Lee et al., "Enhanced colorimetric detection of norovirus using in-situ growth of Ag shell on Au NPs," *Biosensors & Bioelectronics*, vol. 126, pp. 425-432, 2019.
- [32] L. Long, J. Liu, K. Lu et al., "Highly sensitive and robust peroxidase-like activity of Au-Pt core/shell nanorod-antigen conjugates for measles virus diagnosis," *Journal of Nanobiotechnology*, vol. 16, no. 1, p. 46, 2018.
- [33] S. Gao, H. Lin, H. Zhang, H. Yao, Y. Chen, and J. Shi, "Nanocatalytic tumor therapy by biomimetic dual inorganic nanozyme-catalyzed cascade reaction," *Advanced Science*, vol. 6, no. 3, article 1801733, 2019.
- [34] R. C. Bast Jr. and J. F. Holland, *Holland-Frei Cancer Medicine* 8, PMPH-USA, 2010.
- [35] Y. Li, K. H. Yun, H. Lee, S. H. Goh, Y. G. Suh, and Y. Choi, "Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo," *Biomaterials*, vol. 197, pp. 12–19, 2019.
- [36] Y. Hao, Y. Chen, X. He et al., "Polymeric nanoparticles with ROS-responsive prodrug and platinum nanozyme for enhanced chemophotodynamic therapy of colon cancer," *Advanced Science*, vol. 7, no. 20, article 2001853, 2020.
- [37] K. Zhang, M. Tu, W. Gao et al., "Hollow Prussian blue nanozymes drive neuroprotection against ischemic stroke via attenuating oxidative stress, counteracting inflammation, and suppressing cell apoptosis," *Nano Letters*, vol. 19, no. 5, pp. 2812–2823, 2019.
- [38] V. Kumar, A. K. Abbas, and J. C. Aster, *Robbins Basic Pathology*, Elsevier, Philadelphia, Pennsylvania, 2018.
- [39] D. A.-O. Placha and J. A.-O. Jampilek, "Chronic inflammatory diseases, anti-inflammatory agents and their delivery nanosystems," *Pharmaceutics*, vol. 13, 2021.
- [40] J. Zhao, W. Gao, X. Cai et al., "Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease," *Theranostics*, vol. 9, no. 10, pp. 2843–2855, 2019.
- [41] G. Garcia-Rayado, M. Navarro, and A. Lanas, "NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs," *Expert Review of Clinical Pharmacology*, vol. 11, no. 10, pp. 1031–1043, 2018.
- [42] T. Grosser, E. Ricciotti, and G. A. FitzGerald, "The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs," *Trends in Pharmacological Sciences*, vol. 38, no. 8, pp. 733–748, 2017.

- [43] S. Bacchi, P. Palumbo, A. Sponta, and M. F. Coppolino, "Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review," Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, vol. 11, 2012.
- [44] M. Oray, K. Abu Samra, N. Ebrahimiadib, H. Meese, and C. S. Foster, "Long-term side effects of glucocorticoids," *Expert Opinion on Drug Safety*, vol. 15, no. 4, pp. 457–465, 2016.
- [45] J. Vandewalle, A. Luypaert, K. De Bosscher, and C. Libert, "Therapeutic mechanisms of glucocorticoids," *Trends in Endocrinology & Metabolism*, vol. 29, no. 1, pp. 42–54, 2018.
- [46] Y. He, Y. Yue, X. Zheng, K. Zhang, S. Chen, and Z. Du, "Curcumin, inflammation, and chronic diseases: how are they linked?," *Molecules*, vol. 20, no. 5, pp. 9183–9213, 2015.
- [47] T. Hussain, B. Tan, Y. Yin, F. Blachier, M. C. B. Tossou, and N. Rahu, "Oxidative stress and inflammation: what polyphenols can do for us?," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 7432797, 9 pages, 2016.
- [48] N. Liang and D. D. Kitts, "Role of chlorogenic acids in controlling oxidative and inflammatory stress conditions," *Nutrients*, vol. 8, no. 1, 2016.
- [49] K. A. Ahmad, D. Yuan Yuan, W. Nawaz et al., "Antioxidant therapy for management of oxidative stress induced hypertension," *Free Radical Research*, vol. 51, no. 4, pp. 428–438, 2017.
- [50] I. Celardo, J. Z. Pedersen, E. Traversa, and L. Ghibelli, "Pharmacological potential of cerium oxide nanoparticles," *Nanoscale*, vol. 3, no. 4, pp. 1411–1420, 2011.
- [51] A. Karakoti, S. Singh, J. M. Dowding, S. Seal, and W. T. Self, "Redox-active radical scavenging nanomaterials," *Chemical Society Reviews*, vol. 39, no. 11, pp. 4422–4432, 2010.
- [52] C. Xu, Y. Lin, J. Wang et al., "Nanoceria-triggered synergetic drug release based on CeO₂-capped mesoporous silica hostguest interactions and switchable enzymatic activity and cellular effects of CeO₂," Advanced Healthcare Materials, vol. 2, no. 12, pp. 1591–1599, 2013.
- [53] A. Y. Estevez, S. Pritchard, K. Harper et al., "Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia," *Free Radical Biology & Medicine*, vol. 51, no. 6, pp. 1155–1163, 2011.
- [54] R. Pautler, E. Y. Kelly, P. J. J. Huang, J. Cao, B. Liu, and J. Liu, "Attaching DNA to nanoceria: regulating oxidase activity and fluorescence quenching," ACS Applied Materials & Interfaces, vol. 5, no. 15, pp. 6820–6825, 2013.
- [55] Bhargava, A. Arya, N. Sethy, S. Singh, and M. Das, "Cerium oxide nanoparticles protect rodent lungs from hypobaric hypoxia-induced oxidative stress and inflammation," *International Journal of Nanomedicine*, vol. 8, pp. 4507–4520, 2013.
- [56] Y. Guan, M. Li, K. Dong et al., "Ceria/POMs hybrid nanoparticles as a mimicking metallopeptidase for treatment of neurotoxicity of amyloid-β peptide," *Biomaterials*, vol. 98, pp. 92– 102, 2016.
- [57] Q. Bao, P. Hu, Y. Xu et al., "Simultaneous blood-brain barrier crossing and protection for stroke treatment based on edaravone-loaded ceria nanoparticles," ACS Nano, vol. 12, no. 7, pp. 6794–6805, 2018.
- [58] H. J. Kwon, D. Kim, K. Seo et al., "Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson's disease," *Angewandte Chemie (International Ed. in English)*, vol. 57, no. 30, pp. 9408–9412, 2018.
- [59] Y. Liu, M. Yuan, L. Qiao, and R. Guo, "An efficient colorimetric biosensor for glucose based on peroxidase-like protein-

Fe₃O₄ and glucose oxidase nanocomposites," *Biosensors & Bioelectronics*, vol. 52, pp. 391–396, 2014.

- [60] Y. Zhang, Z. Wang, X. Li et al., "Dietary iron oxide nanoparticles delay aging and ameliorate neurodegeneration in Drosophila," *Advanced Materials*, vol. 28, no. 7, pp. 1387–1393, 2016.
- [61] S. Zhao, H. Duan, Y. Yang, X. Yan, and K. Fan, "Fenozyme protects the integrity of the blood-brain barrier against experimental cerebral malaria," *Nano Letters*, vol. 19, no. 12, pp. 8887–8895, 2019.
- [62] F. Xiong, H. Wang, Y. Feng et al., "Cardioprotective activity of iron oxide nanoparticles," *Scientific Reports*, vol. 5, no. 1, p. 8579, 2015.
- [63] X. Liu, Q. Wang, H. Zhao, L. Zhang, Y. Su, and Y. Lv, "BSAtemplated MnO₂ nanoparticles as both peroxidase and oxidase mimics," *Analyst*, vol. 137, no. 19, pp. 4552–4558, 2012.
- [64] N. Singh, M. A. Savanur, S. Srivastava, P. D'Silva, and G. Mugesh, "A redox modulatory Mn3O4Nanozyme with multi-enzyme activity provides efficient cytoprotection to human cells in a Parkinson's disease model," *Angewandte Chemie*, vol. 56, no. 45, pp. 14267–14271, 2017.
- [65] N. Singh, M. A. Savanur, S. Srivastava, P. D'Silva, and G. Mugesh, "A manganese oxide nanozyme prevents the oxidative damage of biomolecules without affecting the endogenous antioxidant system," *Nanoscale*, vol. 11, no. 9, pp. 3855– 3863, 2019.
- [66] J. Yao, Y. Cheng, M. Zhou et al., "ROS scavenging Mn3O4nanozymes forin vivoanti-inflammation," *Chemical Science*, vol. 9, no. 11, pp. 2927–2933, 2018.
- [67] B. Xiong, R. Xu, R. Zhou, Y. He, and E. S. Yeung, "Preventing UV induced cell damage by scavenging reactive oxygen species with enzyme-mimic Au-Pt nanocomposites," *Talanta*, vol. 120, pp. 262–267, 2014.
- [68] S. Zhu, M. Zeng, G. Feng, and H. Wu, "Platinum nanoparticles as a therapeutic agent against dextran sodium sulfate-induced colitis in mice," *International Journal of Nanomedicine*, vol. 14, pp. 8361–8378, 2019.
- [69] S. Onizawa, K. Aoshiba, M. Kajita, Y. Miyamoto, and A. Nagai, "Platinum nanoparticle antioxidants inhibit pulmonary inflammation in mice exposed to cigarette smoke," *Pulmonary Pharmacology & Therapeutics*, vol. 22, no. 4, pp. 340–349, 2009.
- [70] S. Shibuya, Y. Ozawa, K. Watanabe et al., "Palladium and platinum nanoparticles attenuate aging-like skin atrophy via antioxidant activity in mice," *PLoS One*, vol. 9, no. 10, article e109288, 2014.
- [71] L. L. Dugan, L. L. Tian, K. L. Quick et al., "Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates," *Annals of Neurology*, vol. 76, no. 3, pp. 393–402, 2014.
- [72] S. Singh, "Nanomaterials exhibiting enzyme-like properties (nanozymes): current advances and future perspectives," *Frontiers in Chemistry*, vol. 7, p. 46, 2019.
- [73] M. Liang and X. Yan, "Nanozymes: from new concepts, mechanisms, and standards to applications," *Accounts of Chemical Research*, vol. 52, no. 8, pp. 2190–2200, 2019.
- [74] J. Wu, X. Wang, Q. Wang et al., "Nanomaterials with enzymelike characteristics (nanozymes): next-generation artificial enzymes (II)," *Chemical Society Reviews*, vol. 48, no. 4, pp. 1004–1076, 2019.